Aug 2026· Acta Biochimica et Biophysica Sinica· 0 citations· 67 references
Medicine
TL;DR
This platform recapitulates key features of overnutrition, heart failure, and myocardial infarction, including altered contractility, calcium dynamics, and biomarker expression and provides a physiologically relevant platform for studying cardiac disease mechanisms, drug responses, and cardiotoxicity.
Abstract
Cardiovascular diseases remain leading causes of mortality, yet progress in therapy development is limited by inadequate human-relevant models. Here, we develop a simplified, multicellular human iPSC-derived cardiac organoid system that enables functional and translational disease modeling. Using a streamlined two-component differentiation strategy, we generate robust beating cardiomyocytes and assemble three- and four-cell-type organoids incorporating endothelial cells, fibroblasts, and macrophages. Integration of a genetically encoded calcium reporter allows real-time, non-invasive functional assessment. Multicellular organoids exhibit enhanced maturation and viability, with macrophages contributing to improved functional properties. Optimized oxygen-permeable culture further enhances organoid performance. This platform recapitulates key features of overnutrition, heart failure, and myocardial infarction, including altered contractility, calcium dynamics, and biomarker expression. Together, this cost-effective and scalable system provides a physiologically relevant platform for studying cardiac disease mechanisms, drug responses, and cardiotoxicity.
A comprehensive synthesis of current cardiovascular organoid research is presented, emerging biomedical applications are highlighted, and a critical perspective on the ethical frameworks essential for advancing the field responsibly is provided.
Koushik Sen, Suravi Majumder, Dragana Stanišić et al.· American Heart Journal Plus:...· 0 citations
Myocardial infarction (MI) remains a leading cause of death worldwide, and therapies that limit injury, promote repair, and restore cardiac function remain limited. Human induced pluripotent stem cells (hiPSCs) provide a renewable source of patient-specific cardiac cells and have enabled the development of increasingly...
Benjamin B. Johnson, C. Mummery, Richard P. Davis· Cell Reports Medicine· 0 citations
Cardiovascular disease remains the leading cause of death worldwide. However, the limited translational fidelity of traditional preclinical models continues to constrain the development of safer and more effective therapies. Animal studies and static two-dimensional cultures only partially reproduce human cardiac physi...
Caner Dikyol, Alaa Alsaafin, David F. Bodenstein et al.· Advanced Drug Delivery Revie...· 0 citations
This review evaluates recent developments in hiPSC technology, beginning with the generation of patient-specific models of inherited arrhythmias and cardiomyopathies, and examines progress in directing hiPSCs into specialized lineages, including cardiomyocytes, pacemaker cells, and Purkinje fibers.
Berra Koskulu, Tabish Ali, Ilkin Tetik-Altintop et al.· Journal of the American Hear...· 0 citations
This review discusses recent advances in engineering the cardiac developmental niche by integrating extracellular matrix remodeling, biomaterials, biomechanical and bioelectrical stimulation, metabolic regulation, multicellular interactions, and microfluidic technologies to better recapitulate the dynamic microenvironm...
Gustavo Rosero, Ana Belén Peñaherrera-Pazmiño, Camilo Pérez-Sosa· Bioengineering· 0 citations
Abstract Cardiovascular diseases remain the leading cause of global mortality, yet traditional preclinical models fail to accurately capture the physiological and genetic complexity of the human heart, hindering the development of targeted therapies. Cardiac microphysiological systems (cardiac MPS), including self‐orga...
Rong-Fang Xie, Haiyang Zhao, Yuqing Lei et al.· Bioengineering & Translation...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.